Related Experiment Video
Updated: Jun 8, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis
1Department of Liaison Psychiatry, Leicester General Hospital, Leicester, UK. Alex.mitchell@leicspart.nhs.uk
Insights
People with schizophrenia and severe mental illness (SMI) receive suboptimal cardiovascular care, including fewer procedures and medications. This deficit in quality medical treatment may contribute to higher mortality rates in this population.
Area of Science:
- Cardiology
- Psychiatry
- Public Health
Background:
- Individuals with severe mental illness (SMI), including schizophrenia, experience significant health disparities.
- Previous research has documented inequalities in medical care quality for those with mental health conditions.
- The specific impact of these disparities on mortality rates, particularly for cardiovascular conditions, remains unclear.
Purpose of the Study:
- To investigate whether disparities in the medical treatment of cardiovascular conditions are associated with increased mortality in individuals with schizophrenia and SMI.
- To examine the receipt of medical procedures and prescribed medications for cardiovascular conditions in this patient group.
Main Methods:
- A systematic review of studies examining the adequacy of cardiovascular care (procedures and medications) in individuals with schizophrenia and SMI.
- A pooled analysis of prescribed cardiac medications, comparing individuals with and without comorbid mental illness.
- Focus on studies measuring mortality as an outcome.
Main Results:
- Six out of eight studies on cardiac procedures indicated lower-than-average provision of medical care for individuals with schizophrenia.
- Pooled analysis of nine medication studies revealed lower-than-average prescribing rates for angiotensin-converting enzyme inhibitors, beta-blockers, and statins.
- No significant difference in aspirin prescribing was found, while higher-than-expected prescribing of older non-statin cholesterol-lowering agents was observed.
- Ten studies linking poor quality of care to mortality outcomes were identified; half showed significantly higher mortality in individuals with mental ill health, but a causative link was not confirmed due to inadequate data.
Conclusions:
- The quality of medical treatment for cardiovascular conditions in patients with comorbid schizophrenia is frequently suboptimal.
- Deficits in the quality of cardiovascular care likely contribute to higher-than-expected mortality rates in individuals with SMI and schizophrenia.
- Ensuring high-quality medical care for people with severe mental illness is crucial to address avoidable excess mortality.
Abstract:
We have previously documented inequalities in the quality of medical care provided to those with mental ill health but the implications for mortality are unclear. We aimed to test whether disparities in medical treatment of cardiovascular conditions, specifically receipt of medical procedures and receipt of prescribed medication, are linked with elevated rates of mortality in people with schizophrenia and severe mental illness. We undertook a systematic review of studies that examined medical procedures and a pooled analysis of prescribed medication in those with and without comorbid mental illness, focusing on those which recruited individuals with schizophrenia and measured mortality as an outcome. From 17 studies of treatment adequacy in cardiovascular conditions, eight examined cardiac procedures and nine examined adequacy of prescribed cardiac medication. Six of eight studies examining the adequacy of cardiac procedures found lower than average provision of medical care and two studies found no difference. Meta-analytic pooling of nine medication studies showed lower than average rates of prescribing evident for the following individual classes of medication; angiotensin converting enzyme inhibitors (n = 6, aOR = 0.779, 95% CI = 0.638-0.950, p = 0.0137), beta-blockers (n = 9, aOR = 0.844, 95% CI = 0.690-1.03, p = 0.1036) and statins (n = 5, aOR = 0.604, 95% CI = 0.408-0.89, p = 0.0117). No inequality was evident for aspirin (n = 7, aOR = 0.986, 95% CI = 0.7955-1.02, p = 0.382). Interestingly higher than expected prescribing was found for older non-statin cholesterol-lowering agents (n = 4, aOR = 1.55, 95% CI = 1.04-2.32, p = 0.0312). A search for outcomes in this sample revealed ten studies linking poor quality of care and possible effects on mortality in specialist settings. In half of the studies there was significantly higher mortality in those with mental ill health compared with controls but there was inadequate data to confirm a causative link. Nevertheless, indirect evidence supports the observation that deficits in quality of care are contributing to higher than expected mortality in those with severe mental illness (SMI) and schizophrenia. The quality of medical treatment provided to those with cardiac conditions and comorbid schizophrenia is often suboptimal and may be linked with avoidable excess mortality. Every effort should be made to deliver high-quality medical care to people with severe mental illness.
Related Concept Videos
Psychological and Sociocultural Causes of Schizophrenia
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...